Ceftazidime: Difference between revisions
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
Ceftazidime, sold under the brand name Fortaz among others, is a third-generation [[cephalosporin]] antibiotic useful for the treatment of a number of bacterial infections. Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, Pseudomonas aeruginosa infection, and vibrio infection.<ref name="a1">[https://www.drugs.com/monograph/ceftazidime.html "Ceftazidime".] The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.</ref> See also [https://en.wikipedia.org/wiki/Ceftazidime Ceftazidime]. | Ceftazidime, sold under the brand name Fortaz among others, is a third-generation [[cephalosporin]] antibiotic useful for the treatment of a number of bacterial infections. Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, Pseudomonas aeruginosa infection, and vibrio infection.<ref name="a1">[https://www.drugs.com/monograph/ceftazidime.html "Ceftazidime".] The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.</ref> See also [https://en.wikipedia.org/wiki/Ceftazidime Ceftazidime]. | ||
Third-generation cephalosporins differ from earlier generations in the presence of a C=N-OCH3 group in their chemical structure (cefuroxime & cefuzonam also bear this functional group but are only listed as class II). This group provides improved stability against certain [[beta-lactamase]] enzymes produced by Gram-negative bacteria. These bacterial enzymes rapidly destroy earlier-generation cephalosporins by breaking open the drug's beta-lactam chemical ring, leading to antibiotic resistance. Though initially active against these bacteria, with widespread use of third-generation cephalosporins, some Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs) are even able to inactivate the third-generation cephalosporins. Infections caused by ESBL-producing Gram-negative bacteria are of particular concern in hospitals and other healthcare facilities.<ref name="a19">PMID:24298468</ref> | |||
<scene name='10/1041498/Cv/2'>Penicillin-binding protein PBP3 complexed with ceftazidime</scene> ([[3pbo]]). | |||
<scene name='10/1041498/Cv/5'>Ceftazidime binding site</scene>. Water molecules are shown as red spheres. | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Latest revision as of 10:02, 7 April 2024
Ceftazidime, sold under the brand name Fortaz among others, is a third-generation cephalosporin antibiotic useful for the treatment of a number of bacterial infections. Specifically it is used for joint infections, meningitis, pneumonia, sepsis, urinary tract infections, malignant otitis externa, Pseudomonas aeruginosa infection, and vibrio infection.[1] See also Ceftazidime. Third-generation cephalosporins differ from earlier generations in the presence of a C=N-OCH3 group in their chemical structure (cefuroxime & cefuzonam also bear this functional group but are only listed as class II). This group provides improved stability against certain beta-lactamase enzymes produced by Gram-negative bacteria. These bacterial enzymes rapidly destroy earlier-generation cephalosporins by breaking open the drug's beta-lactam chemical ring, leading to antibiotic resistance. Though initially active against these bacteria, with widespread use of third-generation cephalosporins, some Gram-negative bacteria that produce extended-spectrum beta-lactamases (ESBLs) are even able to inactivate the third-generation cephalosporins. Infections caused by ESBL-producing Gram-negative bacteria are of particular concern in hospitals and other healthcare facilities.[2] (3pbo). . Water molecules are shown as red spheres. |
| ||||||||||
ReferencesReferences
- ↑ "Ceftazidime". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
- ↑ Sharma M, Pathak S, Srivastava P. Prevalence and antibiogram of Extended Spectrum β-Lactamase (ESBL) producing Gram negative bacilli and further molecular characterization of ESBL producing Escherichia coli and Klebsiella spp. J Clin Diagn Res. 2013 Oct;7(10):2173-7. PMID:24298468 doi:10.7860/JCDR/2013/6460.3462